The future of hepatitis C among people who inject drugs: new frontiers for policy, practice and science

In programme
5 sessions 29 presentations View the programme

About

The International Network on Hepatitis and Substance Users (INSHU) has co-produced the track entitled ‘The future of hepatitis C among people who inject drugs: new frontiers for policy, practice and science’. This track will bring together stakeholders (researchers, politicians, policymakers and the affected community) in the areas of drug user health and hepatitis C to discuss future challenges for policy, practice and science in relation to drug use and hepatitis C among people who inject drugs.

Sessions

  • Plenary session
  • Poster session
  • Big debate
  • Structured session
  • Workshop
  • Oral presentation session
  • Short communication session
  • Poster guided tour

Wednesday, 23 October

13:20

The future of hepatitis C among people who inject drugs

13:20 to 14:50
Main stage
Dagmar HedrichErika Duffell
15:00
Practical tools developed under the EMCDDA ‘Harm reduction initiative’

Enhancing the role of drug treatment services for HCV elimination among people who inject drugs

15:00 to 16:30
Central square 1 (C1)
Dagmar HedrichMatthew Hickman

Epidemiology of hepatitis C among people who use drugs — Data to inform future planning

15:00 to 16:30
Insights zone 3 (I3)
Vana SypsaJack Stone

Thursday, 24 October

13:20
Evidence to guide future practice and policy

Enhancing hepatitis C treatment outcomes among people who use drugs

13:20 to 14:50
Insights zone 1 (I1)
Catharina MatheïAdrian Dunlop
16:50

Striving towards the future elimination of Hep C among people who use drugs

16:50 to 18:20
Futures zone 1 (F1)
Eberhard SchatzPerrine Roux

Presentations

  • Plenary session
  • Poster session
  • Big debate
  • Structured session
  • Workshop
  • Oral presentation session
  • Short communication session
  • Poster guided tour

Wednesday, 23 October

13:20
Oral presentation

The epidemiology of drug use and hepatitis C — Where are we now?

13:20 to 13:35
Main stage
Sarah Larney
13:35
Oral presentation

What future strategies will enhance integration of care for drug use and hepatitis C?

13:35 to 13:50
Main stage
Jason Grebely
13:50
Oral presentation

How can modelling inform future interventions to integrate hepatitis C care and drug user health?

13:50 to 14:05
Main stage
Matthew Hickman
14:05
Oral presentation

What is the future role of policy makers to facilitate better integration of hepatitis C and drug user health?

14:05 to 14:20
Main stage
Ricardo Baptista Leite
14:20
Oral presentation

What is required for better integration of hepatitis C and drug user health in the future: a community perspective?

14:20 to 14:35
Main stage
Mauro Guarinieri
14:35

INHSU Connecting with Care Video: Meaningful involvement of people with lived experience in HCV care delivery

14:35 to 14:40
Main stage
15:00
Oral presentation

The EMCDDA 'Harm reduction initiative' to promote access to hepatitis testing and care

15:00 to 15:15
Central square 1 (C1)
Klaudia Palczak
Oral presentation

The contribution of injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at country level: a modelling study

15:00 to 15:15
Insights zone 3 (I3)
Adam Trickey
15:15
Oral presentation

A checklist to identify barriers to HCV testing and linkage to care in drug treatment settings – an important element of a diagnostic process

15:15 to 15:25
Central square 1 (C1)
Ruth Zimmermann
Oral presentation

Factors associated with HIV and hepatitis C in the context of routes of drug administration among problem drug users in Latvia, 2018

15:15 to 15:30
Insights zone 3 (I3)
Laura Isajeva
15:25
Oral presentation

The Knowledge questionnaire for staff working with PWID: feedback from a pilot study among 150 health service workers

15:25 to 15:35
Central square 1 (C1)
Nicola Singleton
15:30
Oral presentation

Barriers in the treatment of HCV infection in drug users: inspiring solutions from SCUDO project

15:30 to 15:45
Insights zone 3 (I3)
Felice Alfonso Nava
15:35
Oral presentation

How HCV testing and care can be delivered through drug services: Evidence-base, case studies and 'real life' implementation experiences

15:35 to 15:55
Central square 1 (C1)
Dagmar HedrichEberhard Schatz
15:45
Oral presentation

HCV care in an opiate substitution therapy program: assessment of infection, liver-related damage, and treatment rates.

15:45 to 16:00
Insights zone 3 (I3)
Roberto Muga
15:55
Oral presentation

Roundtable discussion: identifying barriers and facilitators to HCV testing and access to hepatitis treatment-experience from two European countries

15:55 to 16:30
Central square 1 (C1)
Nadine BerndtRita Cardoso SeixasKarolina Zakrzewska
16:00
Oral presentation

Slamming, drug injection in sexual contexts: increased HIV and HCV exposure for MSM points to a need for intersectional approaches to harm reduction

16:00 to 16:15
Insights zone 3 (I3)
Marie Jauffret-Roustide
16:15
Oral presentation

Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: a systematic review and meta-analysis

16:15 to 16:30
Insights zone 3 (I3)
Jason Grebely

Thursday, 24 October

13:30
Oral presentation

HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care

13:30 to 13:45
Insights zone 1 (I1)
Matthew Hickman
13:45
Oral presentation

Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany

13:45 to 14:00
Insights zone 1 (I1)
Bernd Schulte
14:00
Oral presentation

Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme

14:00 to 14:15
Insights zone 1 (I1)
Brian Conway
14:15
Oral presentation

Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST

14:15 to 14:30
Insights zone 1 (I1)
Tina McHugh
14:30
Oral presentation

The cost-effectiveness of an HCV outreach intervention for at risk populations in London

14:30 to 14:45
Insights zone 1 (I1)
Zoe Ward
Oral presentation

Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data

14:30 to 14:45
Insights zone 1 (I1)
Norah Palmateer
16:50
Oral presentation

A community-based peer-driven program to reach people who inject drugs, monitor risk behaviours and 'test and treat' for infectious diseases in Athens, Greece: ARISTOTLE HCV-HIV

16:50 to 17:05
Futures zone 1 (F1)
Vana Sypsa
17:05
Oral presentation

Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study

17:05 to 17:20
Futures zone 1 (F1)
Jason Grebely
17:20
Oral presentation

Low HCV-RNA prevalence and low anti HCV incidence in a large national sample of PWID in opioid substitution treatment in Germany: a prospective cohort study

17:20 to 17:35
Futures zone 1 (F1)
Bernd Schulte
17:35
Oral presentation

Monitoring the elimination of hepatitis C and B among people who inject drugs in Europe

17:35 to 17:50
Futures zone 1 (F1)
Thomas Seyler
17:50
Oral presentation

'Towards eliminating viral hepatitis': A critical examination of the performativity of hepatitis C elimination goals and targets

17:50 to 18:05
Futures zone 1 (F1)
Kari Lancaster
18:05
Oral presentation

Evidencing viral elimination futures: modelling, targets and the end of Hep C

18:05 to 18:20
Futures zone 1 (F1)
Tim Rhodes
View all tracks